Journal of Clinical Oncology · 2024 · 26 citations · 16 references
MedicineOncologyMolecular OncologyNeoplasiaThoracic OncologyCancer StagingLung CancerMalignant NeoplasmsOncogene MutationsOncogenic Signaling PathwaysTumor Suppressor GenesDriver Copy Number AlterationsLung Cancer StagingNon-small Cell Lung Cancer Adjuvant TherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentOncogenic Driver Mutations
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See the Appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline .
16
Antonio Passaro, Jing Wang, Yan Wang et al. · Annals of Oncology · 2023 · 396 citations · Full text
Medicine, Oncology, Pharmacology +17
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
Byoung Chul Cho, Shun Lu, Enriqueta Felip et al. · New England Journal of Medicine · 2024 · 375 citations · Full text
Medicine, Oncology, Pharmacology +14
Tony Mok, Kazuhiko Nakagawa, Keunchil Park et al. · Journal of Clinical Oncology · 2024 · 153 citations · Full text
Medicine, Oncology, Pharmacology +17